Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCIB1 in Malignant Melanoma
NCT01138410Phase 2Terminated
- Sponsor
- Scancell
- Start
- May 2010
- Primary completion
- Jul 2017
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of SCIB1 in Malignant Melanoma (MM), sponsored by Scancell. Started May 2010; status: terminated.
02
Drugs
SCIB1
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT01138410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01138410.